SecurityTCDA / Tricida, Inc. (89610F101)
Institutional Owners44
Institutional Shares25,157,653 - 24.14%
Temporary Equity Shares Outstanding104,225,638 shares (as of 2018-06-30)
Institutional Value$ 752,468,000 USD

Institutional Stock Ownership and Shareholders

Tricida, Inc. (NASDAQ:TCDA) has 44 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 25,157,653 shares. Largest shareholders include Orbimed Advisors Llc, Wellington Management Group LLP, Baker Brothers Advisors LP, venBio Select Advisor LLC, Price T Rowe Associates Inc /md/, Vivo Capital, LLC, VHCP Management II, LLC, Cormorant Asset Management, LLC, Adage Capital Partners GP LLC, and JP Morgan Chase & Co.
Tricida, Inc. (NASDAQ:TCDA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-14 13F-HR BARCLAYS PLC 900 27
2018-08-10 13F-HR Artal Group S.A. 100,000 2,990
2018-07-23 13F-HR DUNCKER STREETT & CO INC 13,158 393
2018-07-31 13F-HR TD ASSET MANAGEMENT INC 19,197 574
2018-08-02 13F-HR JENNISON ASSOCIATES LLC 557,319 16,664
2018-08-07 13F-HR Catalyst Capital Advisors LLC 262 8
2018-08-14 13F-HR Foresite Capital Management Iv, Llc 75,000 2,243
2018-08-14 13F-HR Wellington Management Group LLP 3,019,102 88,731
2018-08-14 13F-HR Adage Capital Partners GP LLC 630,751 18,859
2018-08-09 13F-HR BlackRock Inc. 317,689 9,498
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 39,604 1,184
2018-08-14 13F-HR Marshall Wace North America L.P. 33,753 1,009
2018-09-18 13F-HR/A NORTHERN TRUST CORP 14,973 448
2018-08-14 13F-HR Ghost Tree Capital, LLC 186,019 5,562
2018-08-10 13F-HR FEDERATED INVESTORS INC /PA/ 375,000 11,213
2018-08-14 13F-HR WOLVERINE ASSET MANAGEMENT LLC 35,000 1,046
2018-08-14 13F-HR BALYASNY ASSET MANAGEMENT LLC 17,250 516
2018-08-14 13F-HR Cormorant Asset Management, LLC 934,588 27,944
2018-08-14 13F-HR COATUE MANAGEMENT LLC 5,000 150
2018-08-10 13F-HR HENDERSON GROUP PLC 10,000 299
2018-08-14 13F-HR JP Morgan Chase & Co 584,237 17,468
2018-08-13 13F-HR VHCP Management II, LLC 962,696 28,785
2018-08-14 13F-HR ROYAL BANK OF CANADA 100 3
2018-08-13 13F-HR Myda Advisors Llc 12,000 359
2018-08-03 13F-HR Dean Capital Investments Management, Llc 23,077 690
2018-08-13 13F-HR SPHERA FUNDS MANAGEMENT LTD. 20,410 610
2018-08-10 13F-HR Vivo Capital, LLC 991,711 29,652
2018-08-14 13F-HR Redmile Group, LLC 500,000 14,950
2018-08-14 13F-HR Baker Brothers Advisors LP 1,600,000 47,840
2018-08-14 13F-HR/A Monashee Investment Management LLC 1,794
2018-08-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 1,002,900 29,987
2018-08-14 13F-HR MORGAN STANLEY 700 21
2018-08-13 13F-HR LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 28,378 849
2018-08-14 13F-HR Blackstone Group L.P. 10,000 299
2018-08-14 13F-HR ORBIMED ADVISORS LLC 10,889,280 325,589
2018-08-14 13F-HR TUDOR INVESTMENT CORP ET AL 6,895 206
2018-08-14 13F-HR DRIEHAUS CAPITAL MANAGEMENT LLC 369,021 11,034
2018-08-14 13F-HR Alyeska Investment Group, L.P. 25,000 748
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 293,186 8,766
2018-08-14 13F-HR venBio Select Advisor LLC 1,095,764 32,763
2018-08-13 13F-HR Laurion Capital Management LP 125,000 3,738

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Upcoming 3% To 4% Book Value Growth For This 9.2% Yielding BDC Positioned For Rising Rates

2018-07-29 seekingalpha
HTGC has recently announced plenty of good news and will likely be reporting strong results for Q3 and Q4 2018. (33-2)

Stocks To Watch: FANGs Out In Tech

2018-07-21 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (675-4)

Tricida IPO: Almost Completed Phase 3 And A Massive Total Addressable Market

2018-07-08 seekingalpha
Tricida is trying to sell 10.3 million shares at $16-18 per share, which will trade on the Nasdaq under the symbol TCDA. (10-1)

Rounds Report: Endocyte Rallied While The Tricida IPO Was A Success

2018-07-06 seekingalpha
The overall bioscience market enjoyed a strong trading day. Many equities under our coverage continued to log further gains for shareholders. (3-3)

IPO News This Week: Market Takes A Holiday After Record Week

2018-07-01 247wallst
Last week’s initial public offering (IPO) calendar included 13 firms looking to enter the public markets. All but one were successful and raised a total of around $2.3 billion in new capital, about $500 million less than planned. The coming week with its July 4 holiday falling on Wednesday has no IPOs scheduled. (6-2)

CUSIP: 89610F101